Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815067) titled 'A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity' on Sept. 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Novo Nordisk A/S

Condition: Overweight Obesity

Intervention: Drug: Zenagamtide injection

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 7, 2026

Target Sample Size: 320

Countries of ...